Nevertheless, EZH2 expression supports the activity of tumor-specific effector T cells in ovarian cancer [68] and restrains the expansion of MDSCs in murine models of lung and colon cancer [44], indicating that EZH2 inhibitors can also impair antitumor immunity. Here, EZH2 is linked to colonic neoplasm.